Development of the Commercial Manufacturing Process for Ipatasertib
Ipatasertib is a potent small molecule Akt kinase inhibitor currently being tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the com...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
Swiss Chemical Society
2021-08-01
|
| Series: | CHIMIA |
| Subjects: |
| id |
doaj-670ffc3b70804677822b0735a25d1d8b |
|---|---|
| record_format |
Article |
| spelling |
doaj-670ffc3b70804677822b0735a25d1d8b2021-08-27T11:22:13ZdeuSwiss Chemical SocietyCHIMIA0009-42932673-24242021-08-01757/860561310.2533/chimia.2021.605Development of the Commercial Manufacturing Process for IpatasertibStephan Bachmann0Hans Iding1Christian Lautz2Isabelle Thomé-Pfeiffer3Caroline Maierhofer4Régis Mondière5Christoph Strasser6Thomas Bär7André Aebi8Andre Schuster9Philipp Schmidt10Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDottikon Exclusive Synthesis AG, Hembrunnstrasse 17, CH-5605 Dottikon, SwitzerlandDottikon Exclusive Synthesis AG, Hembrunnstrasse 17, CH-5605 Dottikon, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandDepartment of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, SwitzerlandIpatasertib is a potent small molecule Akt kinase inhibitor currently being tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.biocatalysiscatalysisdrug developmentenzymemetal catalysisgreen chemistry |
| collection |
DOAJ |
| language |
deu |
| format |
Article |
| sources |
DOAJ |
| author |
Stephan Bachmann Hans Iding Christian Lautz Isabelle Thomé-Pfeiffer Caroline Maierhofer Régis Mondière Christoph Strasser Thomas Bär André Aebi Andre Schuster Philipp Schmidt |
| spellingShingle |
Stephan Bachmann Hans Iding Christian Lautz Isabelle Thomé-Pfeiffer Caroline Maierhofer Régis Mondière Christoph Strasser Thomas Bär André Aebi Andre Schuster Philipp Schmidt Development of the Commercial Manufacturing Process for Ipatasertib CHIMIA biocatalysis catalysis drug development enzyme metal catalysis green chemistry |
| author_facet |
Stephan Bachmann Hans Iding Christian Lautz Isabelle Thomé-Pfeiffer Caroline Maierhofer Régis Mondière Christoph Strasser Thomas Bär André Aebi Andre Schuster Philipp Schmidt |
| author_sort |
Stephan Bachmann |
| title |
Development of the Commercial Manufacturing Process for Ipatasertib |
| title_short |
Development of the Commercial Manufacturing Process for Ipatasertib |
| title_full |
Development of the Commercial Manufacturing Process for Ipatasertib |
| title_fullStr |
Development of the Commercial Manufacturing Process for Ipatasertib |
| title_full_unstemmed |
Development of the Commercial Manufacturing Process for Ipatasertib |
| title_sort |
development of the commercial manufacturing process for ipatasertib |
| publisher |
Swiss Chemical Society |
| series |
CHIMIA |
| issn |
0009-4293 2673-2424 |
| publishDate |
2021-08-01 |
| description |
Ipatasertib is a potent small molecule Akt kinase inhibitor currently being tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis. |
| topic |
biocatalysis catalysis drug development enzyme metal catalysis green chemistry |
| work_keys_str_mv |
AT stephanbachmann developmentofthecommercialmanufacturingprocessforipatasertib AT hansiding developmentofthecommercialmanufacturingprocessforipatasertib AT christianlautz developmentofthecommercialmanufacturingprocessforipatasertib AT isabellethomepfeiffer developmentofthecommercialmanufacturingprocessforipatasertib AT carolinemaierhofer developmentofthecommercialmanufacturingprocessforipatasertib AT regismondiere developmentofthecommercialmanufacturingprocessforipatasertib AT christophstrasser developmentofthecommercialmanufacturingprocessforipatasertib AT thomasbar developmentofthecommercialmanufacturingprocessforipatasertib AT andreaebi developmentofthecommercialmanufacturingprocessforipatasertib AT andreschuster developmentofthecommercialmanufacturingprocessforipatasertib AT philippschmidt developmentofthecommercialmanufacturingprocessforipatasertib |
| _version_ |
1721188213902540800 |